News
NerPharMa Appoints Claudio Salvagnini as Deputy CEO
Nerpharma is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.
Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company’s strategic direction and ensuring operational efficiency.
(Click the title for the complete article)
SIMIS Srl Announces Nomination of Laurent Contaut as the new CEO of SIMIS, a company part of NMS Group
SIMIS Srl (SIMIS), a NMS Group company, is pleased to announce the appointment of Laurent Contaut as the new Chief Executive Officer (CEO) of the organization, effective immediately. The appointment of Laurent comes at an exciting time for SIMIS, as the company continues to expand its services and drive innovation in the pharmaceutical and biotech industries.
(Click the title for the complete article)
NerPharMa Appoints Vittorio Montanaro as New Head of Quality to Strengthen Commitment to Excellence
NerPharMa Srl (part of NMS group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as new Head of Quality, effective immediately. In this role, Vittorio will lead the Quality Assurance, Quality Control and Regulatory Affairs to ensure the highest standards of quality, safety and compliance across NerPharMa’s extensive range of services, offered through both Drug Substances and Drug Product divisions. Vittorio will cover also the role of Qualified Person.
(Click the title for the complete article)
NMS Group certified as “Workplace that promotes health initiatives” again in 2022
NMS group has joined the WHP program since 2017. The Workplace Health Promotion (WHP) is the combined efforts of employers, employees and society to improve the health and well-being of people at work. The promotion of a comfortable and healthy workplace has been one of the goals of NMS group since 2017.
(Click the title for the complete article)
NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth
NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)
NerPharMa Srl Announces Change in Board Composition Effective Today
Nerviano_October_1_2022_NerPharMa Srl, leading CMO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico Pesenti, effective today. Hugues Dolgos, Pharm.D., CEO of NMS Group, is appointed as Sole Director of NerPharMa Srl.
(Click the title for the complete article)
NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022
Nerviano, 29 June 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
(Click the title for the complete article)
Nerviano Medical Sciences signs research agreement with Università del Piemonte Orientale, Faculty of Pharmaceutical Sciences
Nerviano, 28 June 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.
(Click the title for the complete article)
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.
Nerviano, 31 May 2022
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer. BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari: Transport Oncophysics. BrYet will collaborate with our strategic production partner NerPharMa, a leading CDMO in oncology, to scale-up the drug substance manufacturing process and the finished product to supply material for clinical programs with potential upside to future world-wide commercial sales. The company’s goal is to start ML-016 clinical trials in the second half of 2023.
(Click the title for the complete article)
NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO
Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly. (Click the title for the complete article)
Welcome and Check out our new motion picture!